Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Part B Competitive Purchasing Program Gains Flexibility In House-Passed Bill

Executive Summary

Physicians could sign up for Medicare's competitive acquisition program for Part B drugs at any time, rather than only during limited enrollment windows, under a provision of the Children's Health and Medicare Protection Act, which cleared the House Aug. 1

You may also be interested in...



BioScrip, McKesson Among Bidders For Next Medicare Part B CAP Contract

February 15 marked the closing date for potential vendors to submit bids to provide Part B drugs under the Medicare competitive acquisition program for the years 2009-2011, with two companies confirmed as participating in the process

BioScrip, McKesson Among Bidders For Next Medicare Part B CAP Contract

February 15 marked the closing date for potential vendors to submit bids to provide Part B drugs under the Medicare competitive acquisition program for the years 2009-2011, with two companies confirmed as participating in the process

Benzodiazepine Coverage Among Medicare Provisions In Child Health Bill

Makers of benzodiazepines could see wider use of their products by Medicare Part D enrollees, under a provision of the child health/Medicare legislative package that cleared the House Ways and Means Committee July 27

Latest Headlines
See All
UsernamePublicRestriction

Register

PS048654

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel